Market research
BDQM.F Albireo Pharma, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 859M
- P/E ratio
- Not available
- Analyst target
- 75.86
- Dividend yield
- 0.0%
- Beta
- 1.04
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US01345P1066
- Market cap
- 859M
- P/E ratio
- Not available
- Analyst target
- 75.86
- Dividend yield
- 0.0%
- Beta
- 1.04
About
About Albireo Pharma, Inc
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts. As of March 1, 2023, Albireo Pharma, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BDQM.F discussion.
5 years, 5 months ago
Albireo Pharma, Inc is currently in a long term downtrend where the price is trading 1.6% below its 200 day moving average.
From a valuation standpoint, the stock is 94.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 67.0.
Albireo Pharma, Inc's total revenue sank by 57.8% to $3M since the same quarter in the previous year.
Its net income has dropped by 229.7% to $-25M since the same quarter in the previous year.
Finally, its free cash flow fell by 127.1% to $-28M since the same quarter in the previous year.
Based on the above factors, Albireo Pharma, Inc gets an overall score of 1/5.